Literature DB >> 2330488

Drug interactions with fluconazole.

J D Lazar1, K D Wilner.   

Abstract

Fluconazole, a water-soluble bis-triazole antifungal agent that effectively penetrates the cerebrospinal fluid, is a highly selective inhibitor of the fungal cytochrome P450 system. In single-dose studies, coadministration of cimetidine and fluconazole (100 mg) resulted in an insignificant decrease in the absorption of fluconazole. The coadministration of rifampin and fluconazole (200 mg) decreased both the half-life and the area under the plasma concentration-time curve (AUC) of fluconazole. In multiple-dose studies, fluconazole (50 mg) did not significantly alter the pharmacokinetics of the two steroid components of an oral contraceptive. Coadministration of tolbutamide with fluconazole (100 mg) increased both the maximal plasma concentration and the AUC of tolbutamide without changing levels of blood glucose. The coadministration of cyclosporin A with a low dose of fluconazole (100 mg) was not associated with significant changes in the minimal and the maximal plasma concentrations of cyclosporin A. While higher doses of fluconazole (200 mg) did not affect endogenous steroids, coadministration resulted in changes in the pharmacodynamics of warfarin and the pharmacokinetics of phenytoin and cyclosporin A.

Entities:  

Keywords:  Androgens; Biology; Drug Interactions; Drugs--pharmacodynamics; Endocrine System; Examinations And Diagnoses; Hormones; Laboratory Examinations And Diagnoses; Metabolic Effects; Physiology; Testosterone--analysis; Treatment

Mesh:

Substances:

Year:  1990        PMID: 2330488     DOI: 10.1093/clinids/12.supplement_3.s327

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  52 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

2.  Guidelines on the management of tuberculosis and HIV infection in the United Kingdom. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  BMJ       Date:  1992-05-09

3.  Systemic antifungal drugs: Are we making any progress?

Authors:  M Laverdière
Journal:  Can J Infect Dis       Date:  1994-03

4.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 5.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

6.  Fluconazole-associated acute adrenal insufficiency.

Authors:  J D Gradon; D V Sepkowitz
Journal:  Postgrad Med J       Date:  1991-12       Impact factor: 2.401

7.  The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers.

Authors:  Manami Oda; Tsutomu Kotegawa; Kimiko Tsutsumi; Yasukiyo Ohtani; Keiji Kuwatani; Shigeyuki Nakano
Journal:  Eur J Clin Pharmacol       Date:  2003-09-27       Impact factor: 2.953

8.  Effect of antimicrobial and antineoplastic drugs on the uptake of fluconazole by human neutrophils and tissue culture cells.

Authors:  I García; A Pascual; C Conejo; J Salvador; E J Perea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

Review 9.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

10.  Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.